GLP-1 medicines forecast $100B+ revenue; glucose control cuts CV risk

In an Invest Like the Best discussion, life-sciences investor Alex Karnal says GLP-1 medicines could exceed $100 billion in annual revenue, positioning them as a potential “once-in-a-lifetime” public health shift. Karnal argues GLP-1 medicines target disease root causes, helping protect against diabetes and reducing heart attack and stroke risk. He links cardiovascular risk to high glucose levels, noting that middle-aged people face a 30%–50% probability of experiencing a heart attack or stroke between ages 40 and 80. He adds that managing glucose levels is key to lowering this risk. He also points to upcoming medical advances in Alzheimer’s, expecting new steps for anti-amyloid medicines later this year, with early intervention potentially slowing cognitive decline. On lifestyle and market dynamics, Karnal says the modern diet promotes inflammation, and he highlights patient preference for weight-loss drugs that are tolerable rather than extreme. He further notes consumer demand for direct access to medications, citing Eli Lilly’s push for non-traditional distribution models. The takeaway for traders: GLP-1 medicines and related metabolic/cardiovascular therapies could drive significant life-sciences growth, while distribution and patient-adherence trends may affect commercial outcomes for major developers and their partners.